



**RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1617**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/691,528
Applicant : Olaf Wilhelm
Filed : October 24, 2003
TC/A.U. : 1617
Examiner : Abigail Manda Cotton

Docket No. : 2923-576
Customer No. : 6449
Confirmation No. : 7396

RESPONSE

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

January 9, 2007

Sir:

In the Office Action dated July 13, 2006, claims 1-19, in the above-identified U.S. patent application were rejected. Reconsideration of the rejections is respectfully requested in view of the following remarks. Claims 1-19 remain in this application.

Claims 1-3, 5, 8-12, 15 and 18-19 were rejected under 35 USC §103(a) as unpatentable over Xing in view of Pentapharm 1998 or Pentapharm 1997. The Pentapharm catalogs clearly indicate that Pefabloc series compounds are for "research, analytical applications and purification processes" at page 17 of the 1997 catalog and at page 18 of the 1998 catalog. Though Xing discloses that a urokinase inhibitor (B-428) was useful in treating breast cancer, one skilled in the